These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28645291)

  • 41. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
    Mountzios G; Terpos E; Syrigos K; Papadimitriou C; Papadopoulos G; Bamias A; Mavrikakis M; Dimopoulos MA
    Transl Res; 2010 May; 155(5):247-55. PubMed ID: 20403580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of pamidronate in Modic type 1 changes: study protocol for a prospective randomized controlled clinical trial.
    Cecchetti S; Pereira B; Roche A; Deschaumes C; Abdi D; Coudeyre E; Dubost JJ; Mathieu S; Malochet-Guinamand S; Tournadre A; Couderc M; Vayssade M; Daron C; Soubrier M
    Trials; 2014 Apr; 15():117. PubMed ID: 24716739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early healing of hydroxyapatite-coated implants in grafted bone of zoledronic acid-treated osteoporotic rabbits.
    Li JP; Li P; Hu J; Dong W; Liao NN; Qi MC; Li JY
    J Periodontol; 2014 Feb; 85(2):308-16. PubMed ID: 23688100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.
    Reid IR; Black DM; Eastell R; Bucci-Rechtweg C; Su G; Hue TF; Mesenbrink P; Lyles KW; Boonen S;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):557-63. PubMed ID: 23293335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Percutaneous vertebroplasty combined with zoledronic acid for the treatment of painful osteolytic spinal metastases in patients with breast cancer.
    Zhang J; Wang Y; Han K; Tang L; Hu H; Wu C; Shen Z; Sun Y; Yao Y
    J Vasc Interv Radiol; 2013 Dec; 24(12):1861-7. PubMed ID: 24144536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease.
    Johannesen J; Briody J; McQuade M; Little DG; Cowell CT; Munns CF
    Bone; 2009 Nov; 45(5):898-902. PubMed ID: 19446052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are the presence of MODIC changes on MRI scans related to "improvement" in low back pain patients treated with lumbar facet joint injections?
    Bianchi M; Peterson CK; Pfirrmann CW; Hodler J; Bolton J
    BMC Musculoskelet Disord; 2015 Sep; 16():234. PubMed ID: 26338033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
    Foroni C; Milan M; Strina C; Cappelletti M; Fumarola C; Bonelli M; Bertoni R; Ferrero G; Maldotti M; Takano E; Andreis D; Venturini S; Brugnoli G; Petronini PG; Zanoni V; Pritzker L; Pritzker K; Parissenti A; Santini D; Fox SB; Bottini A; Generali D
    Breast Cancer Res Treat; 2014 Feb; 144(1):113-21. PubMed ID: 24469643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.
    Little DG; McDonald M; Bransford R; Godfrey CB; Amanat N
    J Bone Miner Res; 2005 Nov; 20(11):2044-52. PubMed ID: 16234978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
    Kroep JR; Charehbili A; Coleman RE; Aft RL; Hasegawa Y; Winter MC; Weilbaecher K; Akazawa K; Hinsley S; Putter H; Liefers GJ; Nortier JWR; Kohno N
    Eur J Cancer; 2016 Feb; 54():57-63. PubMed ID: 26722766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
    J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doses effects of zoledronic acid on mineral apatite and collagen quality of newly-formed bone in the rat's calvaria defect.
    Olejnik C; Falgayrac G; During A; Cortet B; Penel G
    Bone; 2016 Aug; 89():32-39. PubMed ID: 27168397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats.
    Basi DL; Hughes PJ; Thumbigere-Math V; Sabino M; Mariash A; Lunos SA; Jensen E; Gopalakrishnan R
    J Oral Maxillofac Surg; 2011 Nov; 69(11):2698-707. PubMed ID: 21752506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial.
    Ward LM; Choudhury A; Alos N; Cabral DA; Rodd C; Sbrocchi AM; Taback S; Padidela R; Shaw NJ; Hosszu E; Kostik M; Alexeeva E; Thandrayen K; Shenouda N; Jaremko JL; Sunkara G; Sayyed S; Aftring RP; Munns CF
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5222-e5235. PubMed ID: 34228102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.